Sugi Predict

Sugi Predict / Targets / CTSA

CTSA

Lysosomal protective protein · P10619 · CTSA on Sugi Atlas →

39,985 patent compounds predicted against CTSA, 12,998 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1147244 SCHEMBL1147244 0.56 20/20
SCHEMBL319710 SCHEMBL319710 0.56 17/20
SCHEMBL381756 SCHEMBL381756 0.51 17/20
SCHEMBL580317 SCHEMBL580317 0.51 16/20
SCHEMBL587249 SCHEMBL587249 0.51 16/20
SCHEMBL1157183 SCHEMBL1157183 0.50 15/20
SCHEMBL658439 SCHEMBL658439 0.48 15/20
SCHEMBL557936 SCHEMBL557936 0.43 15/20
SCHEMBL666602 SCHEMBL666602 0.52 14/20
SCHEMBL812910 SCHEMBL812910 0.54 13/20
SCHEMBL364911 SCHEMBL364911 0.40 13/20
SCHEMBL363850 SCHEMBL363850 0.38 13/20
SCHEMBL364576 SCHEMBL364576 0.37 13/20
SCHEMBL1172432 SCHEMBL1172432 0.51 12/20
SCHEMBL617039 SCHEMBL617039 0.50 12/20
SCHEMBL168304 SCHEMBL168304 0.47 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL560764) 0.47 12/20
SCHEMBL362630 SCHEMBL362630 0.36 12/20
SCHEMBL1171873 SCHEMBL1171873 0.52 11/20
SCHEMBL361755 SCHEMBL361755 0.41 11/20

Clinical trials — most relevant to CTSA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS PHASE4COMPLETED
Azithromycin Plus Hydroxychloroquine for COVID-19 Infection PHASE3WITHDRAWN
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Stem Cell Gene Therapy for Cystinosis PHASE1/PHASE2COMPLETED
High-Dose Ambroxol in GBA1-Related Parkinson PHASE1/PHASE2UNKNOWN
A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis PHASE1WITHDRAWN
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction EARLY_PHASE1RECRUITING
The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism EARLY_PHASE1UNKNOWN
Respiratory Cathepsins, Proteases Inhibitors and Glycosaminoglycans (GAG) in Mucopolysaccharidosis nanCOMPLETED
Predicting Pancreatic Necrosis Using mitDNA nanUNKNOWN
Screening of Lysosomal Storage Disorders Diseases in Minority Groups nanUNKNOWN
Time Course for Fasting-induced Autophagy in Humans nanWITHDRAWN
SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease nanUNKNOWN
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients nanRECRUITING
Fasting, Exercise, and Diet to Activate Autophagy in Depression nanNOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
The Natural History of Alpha-Mannosidosis nanCOMPLETED
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
Hydroxychloroquin (HCQ) in chILD of Genetic Defect nanCOMPLETED
Autophagy, Oxidative Stress and Hippo Signaling in Human Aortic Aneurysm nanCOMPLETED
Complement Activation in the Lysosomal Storage Disorders nanWITHDRAWN
Cellular Pharmacodynamics of Small Molecules in Lysosomal Storage Disorders nanUNKNOWN
CYSTEA-BONE Clinical Study nanRECRUITING
Autophagy Bladder Cancer nanUNKNOWN
Early Detection and Follow-Up of Patients With Fabry's Disease nanUNKNOWN
Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11) nanCOMPLETED
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity nanCOMPLETED
2-A-Day Study: Twice a Day Meals Study. nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CTSA binder may also engage these)

ProteinNameSimilarity
Q3MI05 — 1.000 Q3MI05 →
P16675 — 1.000 P16675 →
Q9LEY1 — 0.989 Q9LEY1 →
Q9FH05 — 0.985 Q9FH05 →
Q8VY01 — 0.985 Q8VY01 →
Q920A5 — 0.985 Q920A5 →
Q9MAR8 — 0.985 Q9MAR8 →
Q93Y09 — 0.984 Q93Y09 →
O82229 — 0.983 O82229 →
Q920A6 — 0.983 Q920A6 →
Q9ZQQ0 — 0.982 Q9ZQQ0 →
Q1PF08 — 0.982 Q1PF08 →
P37890 — 0.982 P37890 →
Q9LSM9 — 0.981 Q9LSM9 →
Q9HB40 — 0.981 Q9HB40 →
Q9SFB5 — 0.980 Q9SFB5 →
P07519 — 0.980 P07519 →
P52717 — 0.979 P52717 →
Q84W27 — 0.979 Q84W27 →
Q0WPR4 — 0.978 Q0WPR4 →
Q9LSV8 — 0.978 Q9LSV8 →
Q5W727 — 0.978 Q5W727 →
P08819 — 0.977 P08819 →
Q9FH06 — 0.977 Q9FH06 →
PRCP Lysosomal Pro-X carboxypeptidase 0.977 landscape →
Q9D3S9 — 0.976 Q9D3S9 →
Q0WRX3 — 0.976 Q0WRX3 →
Q9M099 — 0.976 Q9M099 →
Q5RBU7 — 0.976 Q5RBU7 →
Q8L9Y0 — 0.976 Q8L9Y0 →